Literature DB >> 10441522

Heregulin regulation of Akt/protein kinase B in breast cancer cells.

W Liu1, J Li, R A Roth.   

Abstract

In the present studies, we demonstrate that heregulin is a potent and rapid activator of the serine/threonine kinase called Akt in the MCF-7 breast cancer cell line but not in 3 other breast cancer cell lines (T47D, HBL-100, and MDA-231). The extent of activation of Akt in the 4 cell lines correlated with the ability of heregulin to activate phosphatidylinositol 3-kinase and inhibition of the kinase blocked Akt activation. A monoclonal antibody to HER2 inhibited the ability of heregulin to activate Akt in the MCF-7 cells. BT474, a breast cancer cell line which overexpresses HER2, had high basal Akt enzymatic activity. This high basal activity was lowered when cells were pre-incubated with an anti-HER2 monoclonal antibody which is used to treat breast cancer patients. Our results indicate that heregulin is a potent activator of Akt and that overexpression of HER2 in breast cancers could also lead to activation of Akt. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441522     DOI: 10.1006/bbrc.1999.1144

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.

Authors:  Katsuaki Ieguchi; Masaaki Fujita; Zi Ma; Parastoo Davari; Yukimasa Taniguchi; Kiyotoshi Sekiguchi; Bobby Wang; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

4.  Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Authors:  F J Esteva; G N Hortobagyi; A A Sahin; T L Smith; D M Chin; S Y Liang; L Pusztai; A U Buzdar; S S Bacus
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

6.  Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.

Authors:  Jau-Chen Lin; Shuenn-Chen Yang; Tse-Ming Hong; Sung-Liang Yu; Qian Shi; Linyi Wei; Hsuan-Yu Chen; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

Review 7.  Involvement of the Akt/PKB signaling pathway with disease processes.

Authors:  Prosenjit Sen; Sebanti Mukherjee; Doel Ray; Sanghamitra Raha
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

8.  Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.

Authors:  Margarita Calvo; Ning Zhu; John Grist; Zhenzhong Ma; Jeffrey A Loeb; David L H Bennett
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

9.  Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Authors:  Karolina Lindberg; Luisa A Helguero; Yoko Omoto; Jan-Åke Gustafsson; Lars-Arne Haldosén
Journal:  Breast Cancer Res       Date:  2011-04-14       Impact factor: 6.466

10.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Authors:  B L Smith; D Chin; W Maltzman; K Crosby; G N Hortobagyi; S S Bacus
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.